NCT01826448 - A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

September 22, 2014

Study Completion Date

September 22, 2014

Conditions

V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

Interventions

DRUG

PLX3397

DRUG

vemurafenib

Trial Locations (6)

37232

Vanderbilt University, Nashville

80012

University of Colorado, Denver, Aurora

90024

UCLA, Los Angeles

98109

Seattle Cancer Care Alliance, Seattle

Unknown

Institute Gustave Roussy, Paris

University Hospital Essen, Essen